Notice of Extraordinary General Meeting of Brain+ A/S
The shareholders of Brain+ A/S are hereby invited to attend an Extraordinary General Meeting on Friday 2nd September 2022 at 09:00 (CEST). The Extraordinary General Meeting will take place at Købmagergade 53, 3. 1150 Copenhagen as a physical event.
Please find the invitation and appendices attached.
For additional information regarding registration, proxy and postal votes please visit www.brain-plus.com/investor.
Contact Information
CEO, Kim Baden-Kristensen + 45 31393317, E-mail: kim@brain-plus.com, Brain+ A/S, Købmagergade 53, 3.
Certified Advisor: Keswick Global AG, + 43 1 740 408 045, E-mail: info@keswickglobal.com
About BRAIN+ [BRAINP]
The mission of Brain+ is to restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia through software-as-medicine applications. Brain+ has developed a set of software-as-medicine technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, put Brain+ in a strong position to grow towards a market leader position in the Digital Therapeutics (DTx) space.
